This report was first published by Endpoints News. To see the original version, click here
The FDA wants more safety information on Eli Lilly’s newly approved obesity pill Foundayo, saying it’s looking for any cardiovascular event or liver damage risks. It has asked the company to provide data from an ongoing trial.
A Lilly spokesperson downplayed the FDA’s request Tuesday, saying the information asked for was “consistent with the agency’s standard approach,” and that “they haven’t identified a new risk.”
您已阅读17%（508字），剩余83%（2543字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。